Pfizer Inc. said on Monday it would buy drug developer Arena Pharmaceuticals for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine. The $100 per share offer is double the last closing price of Arena’s shares, which surged 92 percent to $95.90 in premarket trading. This…